Agilis Biotherapeutics

41 articles about Agilis Biotherapeutics

• PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics

  8/23/2018

  With the acquisition, PTC adds GT-AADC, an adeno-associated virus (AAV) gene therapy that treats Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.

• 

  PTC Therapeutics to Buy Agilis Biotherapeutics in Deal that Could Exceed $945 Million

  7/20/2018

  PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.

• PTC Therapeutics to Acquire Agilis Biotherapeutics

  7/19/2018

  PTC Therapeutics, Inc., today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.

• Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting

  5/14/2018

  Independent Studies Highlight Sustainable Improvements in Children Treated with Investigational Gene Therapy, AGIL-AADC Prevalence of AADC Deficiency Reported

• Agilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit

  5/2/2018

  Markus Peters, Ph.D., Agilis Chief Commercial Officer, to participate in industry leader panel on pricing, reimbursement and market access

• Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia

  10/31/2017

  The EC’s approval follows a positive opinion in July 2017 from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

• Agilis Biotherapeutics Updates On Progress In CNS Gene Therapy Programs

  10/3/2017

• Agilis Biotherapeutics Updates Progress Of Its CNS Gene Therapy For AADC Deficiency

  9/6/2017

• Agilis Biotherapeutics And Gene Therapy Research Institution Enter Into Strategic Partnership

  8/2/2017

• Agilis Biotherapeutics Announces Presentation Of Five Year Follow-Up Data Of Gene Therapy Treatment For AADC Deficiency

  5/11/2017

• Agilis Biotherapeutics Announces Presentation Of Data From Phase I/II Trial For Treatment Of AADC Deficiency

  5/10/2017

• Agilis Biotherapeutics Expands Commercial, Medical Teams

  5/8/2017

• Agilis Biotherapeutics Announces Orphan Designation Approval In Europe For The Treatment Of AADC Deficiency

  12/1/2016

• Agilis Biotherapeutics Achieves FDA "Rare Pediatric Disease" Designation For AADC Gene Therapy Candidate

  11/17/2016

• Agilis Biotherapeutics Announces First Patient Treated In Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency

  11/16/2016

• Agilis Biotherapeutics Announces Authorization Of Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency

  10/11/2016

• Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Friedreich’s Ataxia (FA)

  8/2/2016

• Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Aromatic L-Amino Acid Decarboxylase Deficiency

  6/29/2016

• Agilis Biotherapeutics, First Gene Therapy Company Selected For NIH Therapeutics For Rare And Neglected Diseases Program

  6/27/2016

• Agilis Biotherapeutics Release: Newborn Screening Study For AADC Deficiency Published In Molecular Genetics And Metabolism

  6/2/2016